Ovarian Cancer PDX Models

Patient Derived Xenograft (PDX) models present a true representation of the human heterogeneity of gynecologic malignancies and provide the most accurate approach to predicting an agents efficacy prior to entering the clinic. The CrownBio ovarian cancer PDX collection consists several models including a treatment resistant model. Learn more about these models in the following publication: More

-Predictive Markers of Efficacy for an Angiopoietin-2 Targeting Therapeutic in Xenograft Models.pdf

Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

OV0243 Ovarian Cancer Papillary adenocarcinoma VIEW MODEL Details
OV0250 Ovarian Cancer Endometrioid adenocarcinoma VIEW MODEL Details
OV0273 Ovarian Cancer NA VIEW MODEL Details
OV0276 Ovarian Cancer ADC VIEW MODEL Details
OV0589 Ovarian Cancer NA VIEW MODEL Details
OV1200 Ovarian Cancer ADC VIEW MODEL Details
OV1272 Ovarian Cancer cystadenoma VIEW MODEL Details
OV1286 Ovarian Cancer ADC VIEW MODEL Details
OV1327 Ovarian Cancer Serous papillary cystadenocarcinoma VIEW MODEL Details
OV1365 Ovarian Cancer ADC VIEW MODEL Details